"Heptovax" - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma

Trial Profile

"Heptovax" - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Tertomotide (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms HeptoVax
  • Sponsors Pharmexa
  • Most Recent Events

    • 17 Dec 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 19 Nov 2007 Interim results on the first 21 patients have been reported; final data expected by the end of the second quarter in 2008.
    • 06 Nov 2007 Status changed from recruiting to in progress. Overall, 40 patients have been enrolled. Results from the first 21 patients are expected to be reported by the end 0f 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top